In Brief: Trimedyne
This article was originally published in The Gray Sheet
Executive Summary
Trimedyne: Laser firm's Cardiodyne subsidiary files an IDE to commence clinical trials of its holmium-based myocardial laser revascularization system to treat patients suffering from severe angina and myocardial ischemia who either are unresponsive to, or not suitable for, drug therapy and who have failed coronary artery bypass surgery and/or percutaneous transluminal coronary angioplasty. The system features an 8-watt SuperPulse holmium laser, AutoFire interface and ChannelMaker fiber-optic needle device. AutoFire monitors a patient's electrocardiogram and, based on data obtained, automatically creates a channel in the heart wall when the left ventricle is full of blood...
You may also be interested in...
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.